Video

Dr. Costello on the Role of Daratumumab in Multiple Myeloma

Caitlin Costello, MD, discusses the role of daratumumab in multiple myeloma.

Caitlin Costello, MD, an associate clinical professor of medicine at the University of California, San Diego, discusses the role of daratumumab (Darzalex) in multiple myeloma.

Daratumumab has demonstrated significant clinical activity with deep responses and a manageable safety profile in multiple combination regimens in multiple myeloma, says Costello.

For example, the phase 2 GRIFFIN study revealed that the CD38-directed agent in combination with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) elicited an improved progression-free survival (PFS) and stringent complete response (sCR) rate compared with RVd alone in newly diagnosed, transplant-eligible patients with multiple myeloma.

Moreover, the ongoing MASTER trial may provide insight on the utility of minimal residual disease (MRD) negativity as a means to guide treatment decisions in patients post-transplant, explains Costello. 

Furthermore, the phase 3 CASSIOPEIA study showed higher rates of deep sCRs and improved PFS with the combination of daratumumab, bortezomib, thalidomide (Thalomid), and dexamethasone (DVTd) versus VTd alone in transplant-eligible patients with multiple myeloma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity